Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 860.22M | -676.88M | 155.99M | 619.28M | 611.08M |
| Total Depreciation and Amortization | 1.26B | 980.04M | 1.23B | 1.29B | 1.23B |
| Total Amortization of Deferred Charges | -- | 265.19M | -- | -- | -- |
| Total Other Non-Cash Items | -392.96M | 870.57M | 552.46M | -286.00M | -237.19M |
| Change in Net Operating Assets | -233.34M | 18.85M | 582.01M | 262.22M | -514.50M |
| Cash from Operations | 1.49B | 1.46B | 2.52B | 1.89B | 1.09B |
| Capital Expenditure | -331.74M | -320.17M | -295.65M | -332.85M | -368.52M |
| Sale of Property, Plant, and Equipment | 44.21M | 210.00K | 52.50K | 195.10K | 57.70K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 202.80M | 71.96M | 8.26M | 36.26M | 18.87M |
| Other Investing Activities | -145.09M | 118.86M | -470.38M | -209.08M | -655.69M |
| Cash from Investing | -229.82M | -129.14M | -757.72M | -505.48M | -1.01B |
| Total Debt Issued | 183.56B | 27.49B | 40.00B | 476.82B | 507.64B |
| Total Debt Repaid | -183.53B | -230.99B | -510.88B | -546.37B | -78.03B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -51.60B | -49.98B | 0.00 | 0.00 | -1.88B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.01B | -63.90M | -953.75M | -61.89M | -886.07M |
| Other Financing Activities | -18.02B | -38.57B | -39.64B | -31.30B | 26.76B |
| Cash from Financing | -1.49B | -1.98B | -4.30B | -740.38M | 2.03B |
| Foreign Exchange rate Adjustments | -16.86M | -63.65M | 150.02M | -281.12M | 110.48M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -243.06M | -715.33M | -2.39B | 363.33M | 2.23B |